83 results about "Antiviral protein" patented technology

The invention provides an expression vector containing a recombined blue algae antiviral protein N nucleotide sequence, a host cell containing the expression vector and a method for preparing recombined blue algae antiviral protein on the basis to obtain the recombined blue algae antiviral protein and further proves that the expression vector and/or the host cell and/or the recombined blue algae antiviral protein can be applied to prepare an antiviral medicament. The method of the invention overcomes the disadvantages of low yield, an easily formed inclusion body and difficult purification and the like in the prior art. Peptide mass fingerprinting of the recombined CVN protein prepared by the method is totally consistent with theoretical peptide mass fingerprinting; and an antiviral experiment proves that the recombined protein has good antiviral activity.

The invention relates to anti-viral protein. The anti-viral protein is characterized in that the anti-viral protein is fusion protein and comprises a transmembrane peptide structural domain and a tandem body which is formed through at least two cytosine deaminase structural domains originated from an APOBEC family, a transmembrane peptide structural domain and various cytosine deaminase structural domains. The transmembrane peptide structural domain in the anti-viral protein provided by the invention ensures the anti-viral protein to have the transmembrane capability and to freely shuttle among cells and enters the cells in a non-receptor and non-energy dependent way; the cytosine deaminase structural domains originated from the APOBEC family ensures that the anti-viral protein can effectively inhibit the reproduction of human immunodeficiency virus and/ or hepatitis B virus after entering cells; because the non-essential sequences in the APOBEC family protein molecules are removed, not only the antiviral activity of the APOBEC family protein molecules is preserved, but also the immunogenicity of the anti-viral protein is reduced, and the transmembrane efficiency of the anti-viral protein is enhanced.

The present invention includes compositions and methods for the identification, characterization and use of a novel anti-viral protein that includes a mitochondrial anti-viral signaling protein.

The invention discloses a structure and application of an Enterovirus 71 (EV71) 3C protease and belongs to the field of RNA virus protein. The invention also discloses an application of the 3C protease and a substrate binding groove thereof in drug design. The protein provided by the invention has a special substrate binding groove and new EV71 virus 3C protease drugs are designed according to the spatial structure of the substrate binding groove, thus the inhibitors aiming at the EV71 virus 3C protease, which are more specific and have better effect, can be obtained, potential drug candidates can be provided for the clinical treatment of hand, foot and mouth disease and the EV71 virus 3C protease has very high application value.

The invention discloses a PAP (pokeweed antiviral protein) freeze-dried powder compounding agent as well as a preparation method and an application thereof, in particular to an application in treatment and prevention of HPV (human papillomavirus) virus infection and related diseases. The PAP freeze-dried powder compounding agent comprises PAP freeze-dried powder and a dissolution liquid, wherein components of the PAP freeze-dried powder comprise PAP, phyto-laccasaponin, polysaccharide and cordycepin; and components of the dissolution liquid comprise water, ethanol, phosphate, glycerol, menthol and preservative. The compounding agent prepared by taking PAP as a main component can effectively treat HPV infection, prevent cervical cancer and penis cancer, has a remarkable curative effect on diseases such as CIN (cervical intraepithelial neoplasia), cervical erosion, cervical polyp, cervical hypertrophy and like caused by HPV infection, and has good clinic application prospect.

The complement activation is a risk factor for the morbidity and mortality of novel coronavirus-19 (COVID-19) patients, and is mediated by a highly immunopathogenic nucleocapsid protein (N) in which severe acute respiratory distress syndrome-related coronavirus 2 (SARS-CoV-2) binds to serine protease MASP-2 in the agglutinin pathway of complement activation. According to the invention, a dominant antibody with anti-SARS-CoV-2 virus N protein is separated and identified from a rapidly recovered COVID-19 convalescent person, and the antibody has high binding affinity. In addition, based on the cleavage activity of the complement protease MASP-2 on a specific fluorescence quenching peptide substrate, the invention further develops a virus-free complement hyper-activation analysis method.

The invention discloses an antiviral protein RC28, the amino acid thereof is shown in SEQ ID NO.1, and the preparation method thereof comprises the following steps: crude separation is carried out to obtain crude extract of RC28, molecular sieve chromatography and ion exchange chromatography are used to further carry out separation and purification to obtain RC28 protein product. The antiviral protein RC28 of the invention has good antiviral activity, and provides an efficient and safe new way for treating virus infection, in particular to enveloped virus infection diseases.

The invention relates to the transgenic technology of bombyx mori, in particular to the application of enhancer Hr3 for promoting Hycu-EP32 protein increment expression. The increment expression vector takes a transposition vector pBac [3 * P3 - EGFPafm] as the base vector; and the transposition vector is sequentially connected with enhancer Hr3, a 39kP promotor, a Hycu-EP32 gene and a termination signal sequence. In the invention, transgenic increment expression exogenous antiviral protein is used for preparing anti-BmNPV bombyx mori, which is the first method of improving the resistance of bombyx mori by adopting transgenic increment expression exogenous resistant protein in diapause bombyx mori; the Hycu-EP32 protein can be expressed in each growth period, so as to overcome the defect that the normal bombyx mori cannot express Hycu-EP32, and provide convenience for inhibiting viral breeding by utilizing Hycu-EP32 protein in each period; and the expressed increment of protein increases with viral increment, so as to reduce impact of expression exogenous protein on normal physiological activities and economic characters of bombyx mori, and obviously improve the resistance of bombyx mori.

The invention provides an anti-novel coronavirus Spike protein antibody and an application thereof. The specific antibody against the novel coronavirus S protein is screened from a single-chain antibody library of a non-immune fully human source sequence by utilizing genetic engineering and a phage surface display library technology. The affinity of the antiviral S protein antibody and the virus S protein is between 1 nM and 50 nM, and the antibody has an inhibition effect on the binding of the novel coronavirus S protein and a human receptor ACE2, so that the antiviral S protein antibody has good S protein binding capability and potential neutralization inhibition effect. The invention provides the specific antibody candidate molecule for research and development of diagnostic reagents and antibody drugs for preventing and treating the novel coronavirus (2019-nCoV), treatment of other diseases such as pneumonia caused by the coronavirus, and the like.

The invention discloses application of IFITM3 (interferon induced transmembrane protein 3) packaging exosome to preparation of a dengue virus infection prevention medicine. A preparation method of the exosome comprises the following steps: collecting the supernatant of an HUVEC (Human Umbilical Vein Endothelial Cell) culture medium with high-expressed IFITM3, and performing sucrose density gradient ultracentrifugation on the supernatant to prepare the exosome. The action mechanism is that the exosome with high-expressed IFITM3 can strongly inhibit dengue virus from adsorbing and penetrating host cells. The invention builds a new strategy for resisting dengue virus with the IFITM3 packaging exosome. Whether the antiviral protein packaging exosome can replace interferon to be directly applied to research and development of antiviral medicines opens up a new vision and new application of humanized antiviral protein in the field of antiviral prevention and treatment, thus providing new ideas and directions for development of novel antiviral medicines.

The invention discloses a microparticle chemiluminescence detection kit for immunoassay of antiviral protein MxA, which comprises a coating reaction buffer, a magnetic microparticle solution, a secondantiviral protein MxA monoclonal antibody solution, a first luminescent liquid, a second luminescent liquid, a whole blood lysing solution, different concentrations of antiviral protein MxA antigen standard solution and concentrated washing solution. The invention fills the gap in the production of microparticle chemiluminescence detection reagent for immunoassay of antiviral protein MxA in China, which has the advantages of simple operation, high sensitivity, wide linear range, stable results, good safety, easy automation, and has broad application prospects in clinical testing.

The invention discloses application of an interferon kappa (IFN-kappa) in preparation of anti-enveloped virus medicines, belonging to the field of anti-virus medicines. A nucleotide sequence of a coding gene of the IFN-kappa is as shown in SEQ ID NO:1, and an amino acid sequence is as shown in SEQ ID NO:2; and an enveloped virus comprises but is not limited to flu and ZIKV. The condition that expression of antiviral protein IFITM3 is induced by IFN-kappa is found, so that infection and replication of flu virus and the ZIKV are prohibited. IFN-kappa can effectively prohibit infection and replication of the enveloped-virus in an in-vitro cell model, so as to relieve various diseases caused by massive replication of the flu virus and the ZIKV. The above finding shows that the IFN-kappa can be used for preparing the anti-enveloped virus medicines as well as medicines for treating and/or preventing various diseases caused by the enveloped-virus.

The invention discloses a recombinant protein expressed by an SARS-CoV-2 virus S protein receptor binding region encoding gene, an antibody generated by the recombinant protein and application thereof, and belongs to the field of biomedicine and the field of immunological detection. The encoding gene has a nucleotide sequence as shown in SEQ ID NO: 2. The encoding gene or antibody can be applied to preparation of an antibody for detecting an anti-SARS-CoV-2 virus S protein receptor binding region. The invention discloses an antibody prepared from recombinant protein expressed by the encoding gene and application of the antibody. The encoding gene provided by the invention ensures the uniqueness of protein expression and reduces the difficulty of subsequent purification of the protein. The prepared antibody is high in antigen detection sensitivity and strong in specificity.

The present invention provides antiviral proteins (collectively referred to as cyanovirins), conjugates thereof, DNA sequences encoding such agents, host cells containing such DNA sequences, antibodies directed to such agents, compositions comprising such agents, and methods of obtaining and using such agents.

The invention discloses a structure of a coxsackie virus A16-3C protease and an application thereof, which belong to the field of RNA (Ribose Nucleic Acid) virus proteins. The invention also discloses an application of using a 3C protease and a substrate binding groove in drug design. The protein provided by the invention has a special substrate binding groove; a novel anti-virus CVA16 3C protease drug can be designed according to the space structure of the substrate binding groove so as to obtain a more specific inhibitor with better effect for the virus CVA16 3C protease; therefore, a potential alternative drug is provided for clinically treating hand-foot-and-mouth diseases and very high application values are obtained.

The invention discloses a recombinant antiviral protein, nucleic acid coding the recombinant antiviral protein, a recombinant expression vector comprising the nucleic acid, a transformant comprising the recombinant expression vector, a method for preparing the recombinant antiviral protein and an application of the recombinant antiviral protein to preparation of medicines resistant to porcine reproductive and respiratory syndrome viruses (PRRSV). The recombinant antiviral protein comprises a P9 peptide at a terminal N and an ISG20 protein at a terminal C, wherein the P9 peptide and the ISG20 protein are covalently fused; an amino acid sequence of the P9 peptide is shown in SEQ ID NO.1. The recombinant antiviral protein can effectively inhibit synthesis of ribonucleic acid (RNA) of the PRRSV and block replication of the PRRSV, has very high antiviral ability and high target specificity and also has very low toxicity toward cells.

The invention discloses a novel coronavirus, MERS and influenza A/B virus four-in-one rapid detection kit. A release pad of the detection strip A is sprayed with a colored latex labeled anti-novel coronavirus S1 protein polyclonal antibody and a colored latex labeled capture type anti-influenza A virus monoclonal antibody; a release pad of the detection strip B is sprayed with a colored latex labeledanti-MERS virus S1 protein polyclonal antibody and a colored latex labeled capture type anti-influenza B virus monoclonal antibody; and the detection strip A and the detection strip B are assembledon a duplex clamping plate to form the kit. The detection strip A is used for detecting novel coronavirus and influenza A virus, and the detection strip B is used for detecting MERS and influenza B virus. The kit disclosed by the invention is convenient and rapid in detection, can be used for simultaneously judging four viral epidemic diseases which are difficult to distinguish within 3-15 minutes, can be applied to hospital detection, home detection, epidemic disease investigation and large-scale screening diagnosis, and is suitable for global coronavirus and influenza virus epidemic situation monitoring.

The invention discloses primers for obtaining genes of bovine interferon alpha and a preparation method for recombinant bovine interferon alpha. The preparation method comprises the following steps: a, obtaining genes of bovine interferon alpha; b, constructing a cloning vector; c, constructing an expression vector; d, expressing recombinant protein; e, preparing a recombinant bovine interferon alpha crude product; and f, purifying the bovine interferon alpha crude product. Compared with the prior art, the bovine interferon alpha is a cell factor capable of inducing bovine cells to generate various broad-spectrum antiviral proteins and can be used for treating diseases caused by bovine vesicular stomatitis virus, foot and mouth disease virus, bovine viral diarrhea virus, bovine respiratory syncytial virus, and the like.

The invention provides a method of inhibiting prophylactically or therapeutically an influenza viral infection in a host. The method comprises instilling into or onto a host a cell producing an antiviral protein, antiviral peptide, or antiviral conjugate comprising at least nine contiguous amino acids of SEQ ID NO: 2, wherein the at least nine contiguous amino acids are nonglycosylated and have antiviral activity, whereupon the influenza viral infection is inhibited.

The invention discloses a latex-enhanced immunoturbidimetric assay detection single reagent for antiviral protein MxA and a preparation method thereof. A single reagent is adopted, mixing is not needed, the sensitivity is high, the detection speed is high, various samples such as the whole blood, serum and plasma can be directly measured. Therefore, the reagent can be widely applied to various transmission or scattering analyzers including a common biochemical analyzer, a specific protein analyzer and the like.

Disclosed are recombinant plant cells, plant cell parts, plant parts and transgenic plants containing a DNA molecule comprising a sequence encoding a Pokeweed Antiviral Protein (PAP) II protein. PAP II proteins include full length, wild-type PAP II and substantially nontoxic mutants or analogs including fragments thereof truncated at the C-terminus and other PAP II proteins having an intact catalytic active site amino acid residue E172 but that also have at least one amino acid substitution or deletion, and possess anti-viral and/or anti-fungal activity. DNA molecules comprising sequences encoding the mutants or analogs, as well as the isolated and purified PAP II proteins per se, are also disclosed. Methods of identifying nontoxic PAP II mutants are further disclosed.

Transgenic plants that produce a PAP II protein exhibit anti-viral and/or anti-fungal activity. Virtually all flowering plants are included. Seed derived from the transgenic plants are also provided.